Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells 58,007 Shares of Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insider David Bharucha sold 58,007 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $2.32, for a total transaction of $134,576.24. Following the sale, the insider directly owned 91,993 shares in the company, valued at $213,423.76. This trade represents a 38.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

David Bharucha also recently made the following trade(s):

• On Monday, January 26th, David Bharucha sold 12,245 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $1.93, for a total transaction of $23,632.85.

Milestone Pharmaceuticals Trading Down 3.5%

NASDAQ MIST traded down $0.07 on Wednesday, reaching $1.94. The company had a trading volume of 1,697,941 shares, compared to its average volume of 3,110,069. The stock’s 50 day moving average is $2.23 and its 200-day moving average is $1.96. Milestone Pharmaceuticals Inc. has a 52 week low of $0.63 and a 52 week high of $3.06. The stock has a market cap of $165.23 million, a price-to-earnings ratio of -2.37 and a beta of 0.44. The company has a quick ratio of 8.24, a current ratio of 8.24 and a debt-to-equity ratio of 2.74.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. Equities analysts predict that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several large investors have recently added to or reduced their stakes in MIST. Sapient Capital LLC purchased a new position in shares of Milestone Pharmaceuticals in the third quarter worth about $25,000. Bank of America Corp DE increased its position in shares of Milestone Pharmaceuticals by 200,550.0% in the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after purchasing an additional 16,044 shares during the last quarter. Stephenson & Company Inc. purchased a new position in Milestone Pharmaceuticals in the 3rd quarter worth approximately $40,000. Creative Planning increased its holdings in shares of Milestone Pharmaceuticals by 74.6% in the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after buying an additional 10,000 shares during the last quarter. Finally, Bay Rivers Group raised its position in shares of Milestone Pharmaceuticals by 72.9% during the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock valued at $58,000 after buying an additional 12,170 shares in the last quarter. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Trending Headlines about Milestone Pharmaceuticals

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone launched CARDAMYST nasal spray for U.S. pharmacy availability — a commercial milestone that could begin to drive product revenue and awareness. Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
• Positive Sentiment: Analyst optimism rose after Zacks upgraded MIST from “Hold” to a “Strong Buy” (Zacks Rank #1), which may attract buyers and short‑term momentum flows. All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
• Neutral Sentiment: Trading context: shares are trading below the 50‑day moving average and volume is below the stock’s average, which can mute a sustained bounce despite the product launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto completed sizeable stock sales: 133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93 — material reductions disclosed to the SEC that may worry investors about insider confidence or trigger selling pressure. SEC Form 4 – Joseph Oliveto
• Negative Sentiment: Other insiders (David Bharucha and Lorenz Muller) also sold large blocks on both Dec. 15 (~58k and ~53.6k shares respectively) and Jan. 26 (~12.2k and ~11.2k shares respectively), representing substantial percentage reductions in their holdings. These clustered insider sales intensify negative sentiment. SEC Form 4 – David Bharucha SEC Form 4 – Lorenz Muller
• Negative Sentiment: COO Jeffrey Nelson similarly sold significant shares on Dec. 15 and Jan. 26 (including ~58k on Dec. 15), cutting his stake materially — another factor pressuring sentiment. SEC Form 4 – Jeffrey Edward Nelson

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Zacks Research raised Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th. Wells Fargo & Company raised their price objective on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.